Baseline demographic, clinical, and cognitive characteristics of the Alzheimer's Prevention Initiative (API) Autosomal‐Dominant Alzheimer's Disease Colombia Trial

INTRODUCTION: The API AutosomalDominant AD (ADAD) Colombia Trial is a placebo‐controlled clinical trial of crenezumab in 252 cognitively unimpaired 30 to 60‐year‐old Presenilin 1 (PSEN1) E280A kindred members, including mutation carriers randomized to active treatment or placebo and non‐carriers who...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Alzheimers Dement
Prif Awduron: Rios‐Romenets, Silvia, Lopera, Francisco, Sink, Kaycee M., Hu, Nan, Lian, Qinshu, Guthrie, Heather, Smith, Jillian, Cho, William, Mackey, Howard, Langbaum, Jessica B., Thomas, Ronald G., Giraldo‐Chica, Margarita, Tobon, Carlos, Acosta‐Baena, Natalia, Muñoz, Claudia, Ospina, Paula, Tirado, Victoria, Henao, Eliana, Bocanegra, Yamile, Chen, Kewei, Su, Yi, Goradia, Dhruman, Thiyyagura, Pradeep, VanGilder, Paul S., Luo, Ji, Ghisays, Valentina, Lee, Wendy, Malek‐Ahmadi, Michael H., Protas, Hillary D., Chen, Yinghua, Quiroz, Yakeel T., Reiman, Eric M., Tariot, Pierre N.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: John Wiley and Sons Inc. 2020
Pynciau:
Featured Articles
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7819133/
https://ncbi.nlm.nih.gov/pubmed/32418361
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/alz.12109
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg